Dariohealth Corp. · NASDAQ:DRIO
Dariohealth — Q2 2025 Earnings Presentation
35 slides from Dariohealth's earnings presentation, Aug 12, 2025
Slide 1: Corporate Presentation
DarioHealth Corp. Corporate Presentation
Slide 2: Forward-looking statement
Forward-looking statement This presentation of DarioHealth Corp. (“Dario”, the “Company”, “we” and “our”) and We undertake no obligation to publicly update any forward-looking statements, statements of our management or agents related thereto contain or may contain whether as a result of new informa
Slide 3: Investment Thesis
Investment Thesis One of the most comprehensive and unified product offerings 5 covered conditions with navigation technology to assign users to the correct therapeutic areas Massive data assets Invested in understanding and evaluating over 13B user data points to both build our clinical services an
Slide 4: Commercial progress in 2025
Commercial progress in 2025 2024 Client Base • Signed 36 new clients, bringing the total client base Growth from 47 accounts to 83 accounts • On track to achieve 40 new accounts by the end of 2025 Client Base 2025 Growth • 21 Client wins already since January 1st • 1 National Health Plan Meaningful
Slide 5: Chronic Health Issues Have Created a Massive Epidemic
Chronic Health Issues Have Created a Massive Epidemic Leveraging digital health solutions to tackle rising chronic illness and healthcare costs 75% 6 in 10 4 in 10 $4.1T of aggregate adults in the U.S. adults in the U.S. annual health care costs U.S. healthcare spending have a chronic have two or mo
Slide 6: Glaring Need to Address Challenges Across Chronic Conditions
Glaring Need to Address Challenges Across Chronic Conditions 34.2M 51M Diabetes Behavioral Health $9B Total U.S. 60% BH market Adults in the U.S. have a chronic disease1 $72B COMORBIDITIES: 22.8M Total U.S.Metabolic market People with Diabetes & Hypertension 40% of U.S. adults live with two or more
Slide 7: Our Robust Platform Addresses the Needs of our Customers
PRODUCT-MARKET FIT Our Robust Platform Addresses the Needs of our Customers The market is shifting to companies with single solutions that address multiple conditions because of the growing complexity and friction in managing programs DARIO SOLUTION: Supports member needs across multiple conditions
Slide 8: Digital health market trends
Digital health market trends GLP-1: Beyond Cost Pressures Multi-Condition AI-Driven Weight Loss Drive Digital Care Gap Transformation Adoption GLP-1 market Rising healthcare costs Digital solutions for AI technologies expanding beyond driving employers and multi-condition enabling weight loss into p
Slide 9: Dario's Timeline of Expansion Through Market Consolidation
Dario’s Timeline of Expansion Through Market Consolidation Expansion from D2C and single-condition to B2B2C across multiple conditions Mental Health / Wellness Behavioral Health B2C Musculoskeletal B2B Weight Management Hypertension B2B Diabetes D2C 2016 2017 2018 2019 2020 2021 2022 2023 2024 Launc
Slide 10: Multi-Condition Support for Whole Person Health
PLATFORM OVERVIEW Multi-Condition Support for Whole Person Health Digital solutions and medical devices to support each person's unique health journey, focusing on physical and mental well-being Behavioral Maternal Musculoskeletal Diabetes Weight Hypertension Health Health Management DRIO | Nasdaq l
Slide 11: Care Modalities
Care Modalities Providing effective tools and resources based on member preferences and consumer behavior TYPES OF CARE Behavioral Community and Self-guided Digital Connected Health Education Programs Coaching Tools Devices • Clinically • Clinician-reviewed • Nutrition tracker • Dedicated human • Me
Slide 12: Dario Product Offering
Dario Product Offering 1 2 3 4 Cardiometabolic & Behavioral Full GLP-1 Behavioral Health Health Suite MTB + BH BH only MTB + BH + MSK MTB + BH Connected devices + digital and Digital and human support for Comprehensive offering that Connected devices + digital and human support for MTB stress, anxie
Slide 13: A Configurable System: GLP-1 Behavioral Change Program
A Configurable System: GLP-1 Behavioral Change Program Flexible to create a tailored experience based on the unique goals of our clients and members (10 clients implementing) 1 Onboarding: Support members onboarding to the 1 drug and ensure the drug is being prescribed to the Weight Loss Program rig
Slide 14: Dario's AI3
Dario’s AI3 Dario leverages AI models and user data to drive unique insights, boosting engagement and outcomes for a competitive edge Public AI models Proprietary AI3 data points Curated Gen AI Operational value Member value Customer value • Optimize workflows • Personalization and recommendation •
Slide 15: Dynamic Data Collection to Maintain Engagement
PLATFORM Dynamic Data Collection to Maintain Engagement OVERVIEW Creating an integrated and personalized experience with endless user journeys that drives behavior change ENROLLMENT PERSONALIZED USER EXPERIENCE & INTAKE via connected services for initial data collection Outcomes-Based Engagement 30%
Slide 16: Growing B2B2C Footprint and Reach Over the Last 4 Years
Growing B2B2C Footprint and Reach Over the Last 4 Years Expanding core business of B2B2C (Business-to-Business-to-Consumer) channels to employers and health plans B2B2C Revenue Trajectory Since Launch $20M 6x growth over a 2YR trajectory 85+ Customers/partners added since 2020 across B2B2C/Strategic
Slide 17: Clinical Outcomes and ROI for Clients
PLATFORM OVERVIEW Clinical Outcomes and ROI for Clients Real-world clinical studies have proven product excellence and helped quantify the benefits for clients and members USER EXPERIENCE CLINICAL OUTCOMES ROI App Store Rating 13 mmHg reduction $5,077 in systolic blood pressure for over 66% of membe
Slide 18: Best Performing – ROI for Payers and Comprehensive Solution
Best Performing – ROI for Payers and Comprehensive Solution The only consumer-centric, multi-condition solution with real world clinical studies that show tangible results for payors, employers and end users alike Comprehensive user centric experience drives higher client win rate and sustained user
Slide 19: Dario Differentiation in Market Landscape: Claims & Evidence
Dario Differentiation in Market Landscape: Claims & Evidence 0% 0.5% 1% 1.5% 2% A1c point N w reduction Biased based upon cohort with highest starting A1c mmHG reduction 4 6 8 10 12 N w Contradicted by 2016 6 week study systematic review duration 5% 6% 7% 8% 9% 10% Weight loss % w N User satisfactio
Slide 20: Growing Tier 1 Client Base
GO-TO-MARKET-STRATEGY Growing Tier 1 Client Base Including 12 Fortune 500 clients Partners B2B2C – Employers B2B2C – Insurers B2B - Pharma DRIO | Nasdaq listed |
Slide 21: Pricing For Services (Today)
Pricing For Services (Today) Pharma B2B2C B2C Recurring Platform Membership-driven Membership-driven Services Subscription Fee monthly recurring revenue monthly recurring revenue Stakeholders Pharma Health Plans / Self-Insured Members per channel: Partnerships PBMs Employers (Users on Dario platform
Slide 22: 5X ROI
REVENUE Enrolling & Engaging Members of Existing Accounts GROWTH How Dario works for its customers and members Total eligible Drive Create Power Improve user population enrollment engagement personalization outcomes 40% 35% 75% 2.4 5X ROI Eligible Average member Average member Average number 80 stud
Slide 23: Pharma Partnerships: Proven Results through Independent Claims Data
Pharma Partnerships: Proven Results through Independent Claims Data Value Proposition Lower Cost Per Patient 30-60% Lower recruitment costs than pharma agencies Better Engaged Patients 32%+ After 12 months 10:1 Pharma ROI Higher Conversion To Rx 4X Higher conversion to Rx Improved Adherence 10-20% U
Slide 24: Multiple Avenues of Revenue Growth
REVENUE GROWTH Multiple Avenues of Revenue Growth New conditions and capabilities increase opportunities for sales, current clients, and member enrollment Clients – Employers & Health Plans EXISTING EXISTING + NEW POPULATIONS PROSPECTS Customer success Current: and contract renewals Farming: Hunting
Slide 25: Near Term Growth Through our Largest Partnerships
REVENUE Near Term Growth Through our Largest Partnerships GROWTH Dario targets partners that accelerate sales cycle and give access to large scalable TAM 1.15B 50M MEMBER LIVES: TOTAL ADDRESSABLE 87 Million MARKET: Members* $1.67B* 21M 7M 185M 150M 5M 111.5M 3.5M 65M 700K 11.8M Amwell Aetna Plansour
Slide 26: YoY Financial Profile Evolvement - (GAAP)
YoY Financial Profile Evolvement - (GAAP) ($ in millions) H1 2024 H1 2025 $40 $39.23 Gross Profit $35 Increased by 32.0% $30 $25.46 H1 2024 H1 2025 within a single year $25 $20 100% $15 $12.01 $12.12 80% $10 56.5% $5 60% OPEX $0 43.2% 40% Decreased by 35.1% -$5 -$10 20% -$15 -$20 0% -$18.61 Gross Ma
Slide 27: YoY Financial Profile Evolvement - (Non-GAAP)
YoY Financial Profile Evolvement - (Non-GAAP) ($ in millions) H1 2024 H1 2025 $40 Gross Profit $35 H1 2024 H1 2025 $30 $27.38 Increased by 7.5% 100% within a single year $25 $20.37 $20 $15 $12.01 $12.12 80% 67.6% $10 60% 63.5% $5 OPEX $0 40% Decreased by 25.6% -$5 -$10 20% -$15 -$12.17 0% -$20 Gross
Slide 28: Capital Structure
Capital Structure Balance sheet & capitalization snapshot as of August 8th, 2025 Shares Outstanding Market Cap Common Stock 45,497K $25M Stock Price $0.54 Pre-Funded Warrants 5,635K Preferred Shares as Converted 61,458K 112,590K $61M Warrants 11,436K Min $0.64 Max $2.00 ESOP and RSU’s 9,792K Cash ba
Slide 29: Experienced Executive Management Team
Experienced Executive Management Team Steven Nelson Erez Raphael Chen Franco Yehuda Lara Dodo President and Chief CEO, Board Member Chief Financial Officer Chief Operating Officer Commercial Officer Michal Aberman-Shimon Ofer Liedner Omar Manejwala, M.D. Chief People Officer Strategic Growth Chief M
Slide 30: Board of Directors and Advisors
Board of Directors and Advisors Yoav Shaked Dennis Matheis Dennis M. McGrath Hila Karah Chairman of the Board Board Member Chair of Audit - Board Member Board Member Lawrence Leisure Adam Stern Arnaud Robert Eric Milledge Benefit and Payor Board Member Strategic Advisor Chairman of the Advisor Scien
Slide 31: Non-GAAP Financial Measures
Non-GAAP Financial Measures We have provided in this presentation financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non- GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not neces
Slide 32: Reconciliation between Gross Profit and Gross Margin
Reconciliation between Gross Profit and Gross Margin DRIO | Nasdaq listed |
Slide 33: Reconciliation between Operating Expenses and Operating Expenses (non-GAAP)
Reconciliation between Operating Expenses and Operating Expenses (non-GAAP) DRIO | Nasdaq listed |
Slide 34: Reconciliation between Operating Loss and Operating Loss (non-GAAP)
Reconciliation between Operating Loss and Operating Loss (non-GAAP) DRIO | Nasdaq listed |
Slide 35: Thank You!
Thank You!